A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Metastatic Castrate-Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs ABBV-744 (Primary)
- Indications Acute myeloid leukaemia; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 14 Dec 2018 Planned number of patients changed from 80 to 100.
- 14 Dec 2018 Planned End Date changed from 20 Apr 2020 to 13 Apr 2020.
- 31 Aug 2018 Biomarkers information updated